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Abstract
Blood tests are necessary, easy-to-perform and low-cost alternatives for monitoring of
oncolytic virotherapy and other biological therapies in translational research. Here we
assessed three candidate proteins with the potential to be used as biomarkers in biological
fluids: two glucuronidases from E. coli (GusA) and Staphylococcus sp. RLH1 (GusPlus),
and the luciferase fromGaussia princeps (GLuc). The three genes encoding these proteins
were inserted individually into vaccinia virus GLV-1h68 genome under the control of an
identical promoter. The three resulting recombinant viruses were used to infect tumor cells
in cultures and human tumor xenografts in nude mice. In contrast to the actively secreted
GLuc, the cytoplasmic glucuronidases GusA and GusPlus were released into the superna-
tants only as a result of virus-mediated oncolysis. GusPlus resulted in the most sensitive
detection of enzyme activity under controlled assay conditions in samples containing as lit-
tle as 1 pg/ml of GusPlus, followed by GusA (25 pg/ml) and GLuc (375 pg/ml). Unexpect-
edly, even though GusA had a lower specific activity compared to GusPlus, the substrate
conversion in the serum of tumor-bearing mice injected with the GusA-encoding virus
strains was substantially higher than that of GusPlus. This was attributed to a 3.2 fold and
16.2 fold longer half-life of GusA in the blood stream compared to GusPlus and GLuc
respectively, thus a more sensitive monitor of virus replication than the other two enzymes.
Due to the good correlation between enzymatic activity of expressed marker gene and virus
titer, we conclude that the amount of the biomarker protein in the body fluid semiquantita-
tively represents the amount of virus in the infected tumors which was confirmed by low light
imaging. We found GusA to be the most reliable biomarker for monitoring oncolytic virother-
apy among the three tested markers.
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Introduction
The development of the oncolytic virus therapy of cancer and its progress in clinical testing
require the development of appropriate and reliable tools, such as reporter genes, to monitor
beneficial outcomes as well as potential side effects. Oncolytic virotherapy takes advantage of
tumor specific replication of viruses, which ultimately leads to the destruction of cancer cells
through direct tumor cell lysis and/or activation of the immune system [1]. Therefore,
reporter genes, whose products remain within virus-infected cells can be used for direct
imaging of the spatial location and distribution of the (live) drug in vivo indicating tumor
targeting and a lack of off-target tissue infectivity. However, imaging of patients can be a cost
and time consuming endeavor and might not be appropriate for regular monitoring of the
oncolytic virotherapy. Therefore, reporter gene products that can be released from the
infected cells, either by active secretion or due to tumor cell lysis, would allow easier detec-
tion of the biomarker protein in patient samples such as blood and/or other body fluids.
Such reporter proteins could be easily assessed repeatedly from the blood and would be a
helpful indicator of viral presence in the body. Endogenous biomarkers are limited in such a
utility because they may not be specific to the therapeutic, may lack sensitivity, or their base-
line levels may fluctuate or vary between individuals. Many of these limitations can be over-
come by introducing into the (live) drug a unique reporter gene whose expression is specific
to the activity of the therapeutic agent. If the product of the reporter gene is an enzyme, the
activity of the enzyme may serve as a biomarker providing a quantifiable predictor of thera-
peutic performance of the oncolytic treatment.
Recombinant vaccinia virus (rVACV) strains are among the promising candidates with
oncolytic properties that are currently being evaluated in clinical trials [1–3]. We previously
showed that tissue distribution of rVACV can be assessed in mice by reporter gene-mediated
optical- [4,5], optoacoustic- [6], PET- [7,8], and MR-imaging [6]. In addition, we also estab-
lished a simple, fast and inexpensive blood-based assay to verify rVACV replication in mice [9]
and in human patients [10]. The assay is based on the production of E. coli glucuronidase in
infected cells by the engineered oncolytic vaccinia virus strain GLV-1h68. Since the virus is pri-
marily infecting tumor cells, the enzyme is produced upon expression of the gusA gene in those
cells. Due to virus-mediated cell lysis, it is released and can be detected in the circulation. Using
glucuronidase-specific fluorogenic substrates, the enzymatic activity in serum can be quantified
and shown to increase over time during the tumor colonization process [9]. The method distin-
guishes between the E. coli glucuronidase (GusA) encoded by the virus and the endogenous
mammalian glucuronidase present in mice [11] and in the serum of cancer patients. These two
enzymes are distinguished on the basis of their different pH optima. The mammalian enzyme
has a pH optimum of pH4.8 [12] and has no detectable activity in blood samples when assayed
at pH7.4, the pH used to detect GusA activity.
Similarly, the success of certain therapies e.g. mesenchymal stem cell implantation into the
heart, depends on the correct spatiotemporal location of the therapeutic agent and therefore
would benefit from an imaging monitor that remains permanently with the affected cells or tis-
sues. For other therapies an indirect monitoring by measuring a biomarker, away from the
treatment site, is sufficient as an indicator of the biological responses to the therapeutic inter-
vention. For example, release of a biomarker into the blood stream would be appropriate for a
gene therapy treatment to correct for example a hematological deficiency, where the therapeu-
tic effect would be widespread throughout the body.
Here we compared the E. coli beta-glucuronidase (GusA) with other reporter enzymes in
vitro, in cell culture, as well as in animal experiments. Previously our tests of samples from
human cancer patients undergoing oncolytic vaccinia virus therapy in the clinical trial of
Drug-Encoded Biomarkers
PLOS ONE | DOI:10.1371/journal.pone.0137573 September 8, 2015 2 / 18
manuscript. The specific roles of these authors are
articulated in the ‘author contributions’ section.
Competing Interests: The first author of the paper is
a graduate student at the University of Würzburg in
Professor Szalay’s research group and has no
competing financial interests. Several of the authors
(JS, QZ, AF, JC, UF, AAS) are/were employees and/
or shareholders of Genelux Corporation, a company
with focus on live vector mediated tumor therapy.
This does not alter the authors' adherence to PLOS
ONE policies on sharing data and materials.
GL-ONC1 (Clinical grade GLV-1h68) indicated that the amount of glucuronidase detected in
serum was near the detection limit of the assay [10]. Therefore, a specific goal of this study was
to determine whether the sensitivity of the assay could be improved using either more sensitive
substrates and/or enzymes with greater activity. Other markers included in this study were the
secreted Gaussia princeps luciferase (GLuc) and the cytoplasmic Staphylococcus sp. RLH1 glu-
curonidase (GusPlus), a glucuronidase with reported higher specific activity than GusA [13–
15]. While Gaussia luciferase had already been tested in an oncolytic Herpes simplex virus
strain [16], to our knowledge, GusPlus has not been used as a biomarker in live animals or
patients. In addition, we tested additional fluorogenic and luminogenic substrates for glucu-
ronidases and compared them for improved sensitivity. Our results demonstrated that while
the assay for GusPlus activity displayed superior sensitivity in vitro and in cell culture, the
assay for GusA yielded the best sensitivity in vivo.
Materials and Methods
Construction of plasmids, GusPlus expressing E. coli and rVACV
Codon optimized versions of GLuc (GenBank: AAG54095.1) and GusPlus (GenBank:
AAK29422.1) were synthesized by GenScript and flanked by SalI and PacI sites. Sequences
were cloned into the transfer vectors TK-p11-GLuc and HA-p11-GusPlus respectively. The
recombinant viruses GLV-1h351, GLV-1h352 and GLV-1h408 (Table 1) are derivatives of
GLV-1h68 [5] and were constructed using transient dominant guanosine phosphoribosyltrans-
ferase selection [17].
The recombinant vaccinia virus strain GLV-1h68 was constructed as specified by Zhang
et al. [5] and used as the parental strain for the other virus constructs described in this study.
Gene inserts are Renilla luciferase-Aequorea green fluorescent protein fusion cDNA (Ruc-
GFP), human transferrin receptor cDNA (TrfR), β-galactosidase cDNA (lacZ), E.coli β-glucu-
ronidase cDNA (gusA), Staphylococcus glucuronidase cDNA (gusPlus) and Gaussia luciferase
cDNA (GLuc). Relevant reporter gene constructs used in this study are shown in bold. The
human transferrin receptor cDNA is inserted in reverse (rTrfR) and is therefore not expressed
in GLV-1h68. Promoters are synthetic early/late promoter (PSEL), vaccinia virus early/late P7.5
promoter (P7.5) and the vaccinia virus P11 late promoter (P11). GLV-1h351 and -1h352 were
derived from GLV-1h68 by replacing the PSEL-rTrfR-P7.5-lacZ expression cassette at the TK
locus with the GLuc expression cassette P11-GLuc, which was inserted in both possible orienta-
tions. GLV-1h408 was obtained from GLV-1h68 after replacing the gusA expression cassette at
theHA locus with the P11-gusPlus expression cassette.
For expression and purification of GusPlus, the open reading frame was PCR-amplified
from PCRII-GusPlus using the primers 5'-AAA GGA TCC ATG CTG TAT CCT ATC AAC-3'
and 5'-AAA CTG CAG GTC GAC TTA GTT TTT GTA-3'. The resulting fragment was
digested with BamHI and SalI and after purification was ligated into the equally cut pET-28a
vector. The resulting plasmid pET-28(a)-GusPlus was transformed into E. coli BL21.
Table 1. The reporter enzymes encoding genes in rVACV strains.
rVACV strain F14.5L TK HA
GLV-1h68 PSEL-Ruc-GFP PSEL-rTrfR-P7.5-lacZ P11-gusA
GLV-1h351 non-relevant gene P11-GLuc P11-gusA
GLV-1h352 non-relevant gene (P11-GLuc)inverse P11-gusA
GLV-1h408 PSELRuc-GFP PSELrTrfR-P7.5lacZ P11-gusPlus
doi:10.1371/journal.pone.0137573.t001
Drug-Encoded Biomarkers
PLOS ONE | DOI:10.1371/journal.pone.0137573 September 8, 2015 3 / 18
GusPlus purification
E. coli BL21 pET-28a-GusPlus were grown overnight on a shaker (205 rpm) at 37°C in LB
broth. The overnight culture was used to inoculate 500 ml LB broth and was cultured at 37°C
and 205 rpm until the optical density at 600 nm reached 0.67. At this time, 500 μl of a 1M Iso-
propyl β-D-1-thiogalactopyranoside stock solution was used to induce GusPlus production
and the culture was incubated shaking (60 rpm) at room temperature overnight. The bacteria
were collected by centrifugation and frozen at -80°C. The bacterial pellet was resuspended and
sonicated (3 x 3 min) in 15 ml lysis buffer (150 mMNaCl, 50 mM Tris-base, 5 mM β-mercap-
toethanol, 5 mM imidazole, proteinase inhibitors, pH 7.5) before cellular debris was removed
by centrifugation (25,000 rpm in a 70Ti Beckman Coulter rotor for 40 min at 4°C). The cleared
lysate was then added to 500 μl Superflow Ni-NTA beads (Qiagen GmbH, Hilden, Germany)
and incubated for 2 h at 4°C with agitation. Beads were then transferred to a column and
washed once with 5 ml lysis buffer and 3 times with 5 ml washing buffer (150 mMNaCl,
50 mM Tris-base, 5 mM β-mercaptoethanol, 10 mM imidazole, pH 7.5). The bound protein
was eluted using 5x 500 μl elution buffer (150 mMNaCl, 50 mM Tris-base, 5 mM β-mercap-
toethanol, 500 mM imidazole, pH 7.5). Elution fractions 2–5 were pooled and dialyzed over
night against 150 mMNaCl and 50 mM Tris (pH 7.5). Recovery during purification was evalu-
ated by SDS-PAGE (Fig 1A). The purity of the enzyme was determined to be 95.6% by Coo-
massie-stained SDS-PAGE analysis using the ImageJ 1.45s software (Fig 1B).
Fig 1. Purification of His-tagged GusPlus. A)GusPlus expression was induced in E. coli BL21 pET-28a-
GusPlus and the bacteria were harvested by centrifugation (pellet) after overnight culture at room temperature.
The bacteria were then lysed (lysate) and loaded on Ni-NTA beads onto which His-tagged GusPlus bound
preferentially (GusPlus was clearly reduced in the flow through fraction). The Ni-NTA column was washed
(wash fraction) and the beads in the column were shown to have high amounts of bound GusPlus (pre-elution
beads). The elution fractions 2–5 contained highly enriched His-tagged GusPlus (post-elution beads).B) The
combined, dialyzed elution fractions were analyzed by Coomassie-stained SDS-PAGE and determined to be
95.6%His-taggedGusPlus. Commercially available GusAwas shown to be 49.3% pure by loading on a
Coomassie-stained SDS-PAGE 523 ng of total protein of purified GusPlus (center lane) and 1014 ng of total
protein of GusA (right lane). The equal intensities of the GusPlus and GusA bands demonstrated their
differences in purity.
doi:10.1371/journal.pone.0137573.g001
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Cell culture
African green monkey kidney fibroblasts (CV-1, CCL-70™), the human lung carcinoma A549
(CRM-CCL-185™) and the human prostate cancer PC-3 (CRL-1435™) cells were obtained from
the American Type Culture Collection (ATCC). CV-1 and PC-3 cells were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM) (Mediatech, USA) supplemented with 10% fetal
bovine serum (FBS) (Mediatech, USA) under standard cell culture conditions (37°C and 5%
CO2). A549 cells were cultured in RPMI 1640 media (Mediatech, USA) instead of DMEM.
Viral infection assays
CV-1, A549 and PC-3 cells were seeded onto 24-well plates. After 18–24 hours in culture, the
cells were infected with vaccinia virus at a multiplicity of infection (MOI) of 0.005, unless oth-
erwise specified. Infection was performed using medium supplemented with 1% antibiotic-
antimycotic solution (10,000 units/ml penicillin G, 10,000 μg/ml streptomycin, 25 μg/ml
amphotericin B) (Mediatech, USA) and 2% FBS. Plates were incubated for 1h at 37°C with gen-
tle agitation every 20 min. Afterwards infection medium was replaced by fresh growth medium
without phenol red containing 1% antibiotic-antimycotic solution. At 8, 24, 48, 72 and 96
hours post-infection (hpi) the supernatant was removed and stored at -80°C. Fresh medium
(1 ml) was added to the infected cells which were then also frozen at -80°C. After thawing, all
cell fragments were mechanically removed from the plates by pipetting, followed by ultrasound
treatment to completely disrupt cells.
Animal models
Five to six week old athymic nude mice (Harlan Laboratories, Indianapolis, USA) were each
subcutaneously injected onto the right flank with 5x106 A549 lung cancer cells. Animals were
monitored daily for any sign of mortality, abnormal mobility, hunched posture or other signs
of distress. Tumors were allowed to grow for 16 days before groups of 10 mice were injected
into the retro orbital sinus vein with 2x106 pfu/mouse of GLV-1h68, GLV-1h351, or GLV-
1h408 respectively. One mouse in the GLV-1h351 group did not show successful tumor coloni-
zation (no signal in GLuc- or GusA-assays, absence of plaque forming units in the tumor at the
end of the experiment) and was therefore excluded from the statistical analysis of the experi-
ment. Renilla luciferase activity in tumors of mice injected with GLV-1h68 or GLV-1h408 was
determined weekly by low light imaging. For serum analysis, about 50 μl of blood were col-
lected immediately before and 7, 14, and 21 days after virus injection. Upon euthanization on
day 28 after virus injection, more blood was collected.
Half-life time measurements of the proteins were performed in BALB/c mice (Harlan Labo-
ratories, Indianapolis, USA). Groups of 10 (GusA, GusPlus) or 5 (GLuc) mice were injected i.v.
with an equivalent of 5 μg purified GusA and GusPlus or 20 μg GLuc per mouse. Blood was
collected at different times after injection for marker protein concentration determinations in
the serum using the established marker protein assays (see below). Half-life times were calcu-
lated using the Excel software plug-in program PK Functions (Joel I. Usansky, Atul Desai, and
Diane Tang-Liu, Department of Pharmacokinetics and Drug Metabolism, Allergan, Irvine,
USA).
Ethics statement
These animal studies were approved by and performed in strict accordance with the guidelines
of the Institutional Animal Care and Use Committee (IACUC) of Explora Biolabs, San Diego
(Approval numbers: EB11-025 and EB13-003).
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Glucuronidase assay
The standard protocol for the glucuronidase assays was performed essentially as described pre-
viously [9]. In brief, 5 μl or 10 μl of test or control samples or standard solutions with specified
glucuronidase concentration were added to a 384-well plate (black with optical bottom—
Thermo Fisher Scientific, Rochester, USA), followed by addition of 75 μl or 70 μl test solution,
respectively. The test solution consisted of PBS, 2% FBS supplemented with 0.2 μl 36.5 mM
stock solution (in DMSO) of a fluorogenic glucuronidase substrate (see Table 2 for the glucu-
ronidase substrates used in this study). After one hour incubation at 37°C, the fluorescence
emission of each well was measured using a Spectra Max M5 (Molecular Devices, Sunnyvale,
USA) microplate reader. Results are presented in relative fluorescence units (RFU).
In the luminescent assay, the β-Gus Juice Plus (PJK GmbH, Kleinbittersfeld, Germany) sub-
strate was used. In the 384-well plate format, 37.5 μl of β-Gus Juice was added to 5 μl of sample,
and the mix was incubated for 1 hour at room temperature before adding 37.5 μl of Triggering
reagent. Ten minutes later the luminescence signal was measured for 1000 ms in a Spectra Max
M5 microplate reader. Results are presented in relative light units (RLU). Cell culture or serum
samples containing high glucuronidase concentrations (readings exceeding the linear range of
the assay) were diluted in PBS, 2% FBS prior to testing.
Gaussia luciferase assay
For the standard Gaussia luciferase assay we tested 5 μl or 10 μl test samples and standards
with the Pierce Gaussia Luciferase Glow Assay Kit (Thermo Scientific, Rockford, USA) or the
Gaussia Glow-Juice Kit (PJK GmbH, Kleinbittersfeld, Germany) according to the manufactur-
er’s instructions, but adjusted to a 384-well format (50 μl or 55 μl total volume). Results are pre-
sented in relative light units (RLU).
Renilla luciferase imaging
The activity of Renilla luciferase in tumors was analyzed by low light imaging of isoflurane
anesthetized mice that were i.v. injected with 10 μg coelenterazine (in 100 μl PBS) 5 minutes
before imaging in a small animal low light imager (Bruker, Woodbridge, USA). Renilla lucifer-
ase signal quantification was carried out using the Molecular Imaging software (Bruker, Wood-
bridge, USA).
Statistical analysis and regression curves
Student`s T-test was used to calculate statistical differences between two groups. P-values
<0.05 were considered statistically significant. Statistical significance is indicated by asterisks:
Table 2. Glucuronidase assay substrates.
name abbreviation excitation
wavelength
emission
wavelength
source
6-Chloro-4-methylumbelliferyl β-D-
glucuronide
Cl-MUGlcU 386 nm 445 nm Glycosynth, Warrington, UK
4-Methlyumbelliferyl β-D-glucuronide MUGlcU 365 nm 455 nm Life Technologies, Carlsbad, USA
Carboxyumbelliferyl β-D-glucuronide CUGlcU 386 nm 445 nm Marker Gene Technologies Inc., Eugene,
USA
Fluorescein di-β-D-glucuronide FDGlcU 489 nm 525 nm Life Technologies, Carlsbad, USA
β-Gus Juice Plus GusJuice N/A no ﬁlter PJK GmbH, Kleinbittersdorf, Germany
doi:10.1371/journal.pone.0137573.t002
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 (p<0.05);  (p<0.01);  (p<0.001). Linear regression curves and R2-values were calculated
in Microsoft1 Excel1 2008 for Mac, Version 12.3.6.
Results
In this study, three different reporter enzymes (GusA, GusPlus and GLuc) were compared for
their use to monitor biological therapies of tumors during oncolytic virotherapy. Key parame-
ters such as specificity, linearity, sensitivity and enzyme stability were analyzed for each puri-
fied enzyme. Since Staphylococcus glucuronidase GusPlus was not commercially available, we
overexpressed the GusPlus protein and purified a His-tagged version in E. coli. The enzyme
purity achieved was 95.6%, which was higher than that of the commercially available E. coli
glucuronidase (purity: 49.3%) (Fig 1).
In vitro evaluation of the specificity, linearity and sensitivity
The activity of Gaussia luciferase was assayed using the slightly modified Gaussia luciferase
Glow Assay kit (Pierce). Glucuronidase activity was assayed using five different substrates, four
of which produced a fluorescent signal and one produced a luminescent signal.
The specificity of the assays was determined by running control mouse serum and human
plasma samples with substrate but no added reporter enzyme. No non-specific signals above
background were observed for any of the assays (data not shown). The background in these
assays was determined from the sum of the auto-fluorescence of sample alone and substrate
alone. The lack of signal in these tests confirmed that the levels of endogenous glucuronidase in
mouse and human serum did not contribute to the signal under the conditions of the assays.
Additionally, there was no detectable Gaussia luciferase activity in mouse or human serum.
Thus, the signals above background obtained in these tests would be specific for the rVACV-
expressed reporter enzymes.
Linearity of the standard assays was evaluated by plotting the relative fluorescence units or
the relative light units (for luminogenic assays) over the amount of added enzyme. For these
tests, the background fluorescence or luminescence determined for non-enzyme containing
samples was subtracted. The linear range was defined as the enzyme concentration range over
which the data resulted in a linear regression curve with an R2-value>0.99 and the data values
used were higher than the limit of quantification (see below). The linear range of all these
assays covered at least 3 orders of magnitude (Fig 2). For GLuc, linearity ranged from 20 ng/ml
to the highest concentration tested, 20 μg/ml, and the linear range might extend to higher con-
centrations for this assay.
The sensitivity of the assays was determined by running tests with samples at the low con-
centration end of the linear range. The limit of detection (LOD) and limit of quantification
(LOQ) were defined as 3 and 10 times the standard deviation of the background, respectively.
As for sensitivity, the background was determined for each assay as the signal obtained from
control samples with no added enzyme. Differences in sensitivity of the assays were observed
between enzymes and, for the glucuronidases, between substrates. For GLuc in the standard
assay, the LOD was determined to be 2,000 pg/ml. For GusA, the lowest LOD was 25 pg/ml
using the Cl-MUGlcU substrate. The LOD for GusPlus was 1 pg/ml in the standard assay using
the Cl-MUGlcU substrate. The LOQs for the same assays and substrates were 20,000 pg/ml,
37.5 pg/ml and 12.5 pg/ml for GLuc, GusA and GusPlus, respectively. The LOD for GusPlus
could further be reduced to 0.5 pg/ml by extending the assay time from 1 h to 8 h in the stan-
dard protocol.
Consistent with these results, GusPlus has been reported to have a higher conversion rate of
p-nitrophenyl β-D-glucuronide to p-nitrophenyl than GusA [14,15]. The higher rate of
Drug-Encoded Biomarkers
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GusPlus catalysis has been attributed to a greater structural flexibility of its protein conforma-
tional state due to an increased number of random coils in the secondary structure as well as a
greater solvent accessible surface area of the catalytic residues [13]. Our findings are consistent
with this hypothesis in that the higher catalytic activity of GusPlus was observed regardless of
the substrate being used, 3-fold greater conversion of FDGlcU and 8-fold greater conversion of
the GusJuice substrate, compared to GusA.
For both glucuronidases, the sensitivity was highest when assayed with Cl-MUGlcU as sub-
strate. Reduced sensitivity was observed with MUGlcU and CUGlcU followed by GusJuice and
FDGlcU. The difference in sensitivity of the assays between the highest and lowest sensitivity
substrates was about 2 orders of magnitude. The reason for the lower sensitivity of the assays
using the FDGlcU- (and GusJuice-) substrates is probably due to the less effective conversion
of FDGlcU compared to Cl-MUGlcU by both glucuronidases, rather than any significant dif-
ference in the fluorescence properties of the conversion products.
Activity of rVACV-expressed biomarker enzymes in cell cultures
A comparison of the different reporter enzymes in cells infected with vaccinia viruses was con-
ducted by placing each gene under the control of the same (P11) promoter. GLV-1h68 contains
P11-GusA as its reporter gene, which was inserted into the hemaglutinin gene (HA) locus of
the viral genome. The rVACV-strains GLV-1h351 and GLV-1h352 encode the same codon-
optimized version of Gaussia princeps luciferase (GLuc) under the control of the P11 promoter,
inserted into the thymidine kinase gene (TK) locus, however in opposite orientations. GLV-
1h408 contains a codon-optimized gusPlus gene under the control of the P11 promoter, replac-
ing the gusA expression cassette of GLV-1h68 (Table 1). Thus, GLV-1h68 encodes GusA,
GLV-1h408 encodes GusPlus, and GLV-1h351 and GLV-1h352 encode both GLuc and GusA,
all under control of the same promoter, P11. Therefore, the expression of the reporter enzyme
genes in cells infected with these rVACV strains should be proportional to the amount of virus
replication in those cells, and the amount of enzyme detected should be directly proportional
to the viral titer.
In order to test this, the biomarker enzyme levels of GusA and GLuc were evaluated in cell
cultures using A549, PC-3 and CV-1 cell lines, infected with virus at an MOI of 0.005. Culture
medium and cells harvested at 8, 24, 48, 72 and 96 hpi were assayed for the activity of the
marker enzymes. The data were analyzed individually for each cell type. However, correlations
were calculated only from the combined data that were higher than the LOD of each marker
protein assay determined in these same experiments.
Role of the reporter protein expression cassette orientation in the viral genome. The
virus strains GLV-1h351 and GLV-1h352 were used to compare GLuc and GusA activity in the
same infected cells in culture. The GLuc genes are expressed from the same promoter (P11) in
each strain, the only difference between them is the orientation of the P11-GLuc construct in
the rVACV genome. Cells infected with each of the two strains showed no statistical difference
in the relationship between GLuc activity, GusA activity and virus titer (p>0.44) (S1 Fig).
Therefore, the data for the two strains were combined and treated as a single dataset.
Fig 2. Standard assays of purifiedmarker enzymes. Activity vs enzyme concentration of glucuronidase
assays (GusPlus upper chart; GusA middle) with the fluorogenic substrates Cl-MUGlcU, MUGlcU, (CUGlcU
was also tested and the results were comparable to MUGlcU, data not shown), and FDGlcU, as well as with
the luminogenic GusJuice in human serum are compared. The most sensitive assays for GusPlus and GusA
with Cl-MUGlcU and GLuc with the Pierce Gaussia luciferase Glow Assay kit are compared (lower chart). All
data points considered were above the limits of detection, as determined for each individual assay. Data
points determined to be in the linear range are shown in black while all other data points are shown in grey.
doi:10.1371/journal.pone.0137573.g002
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Reporter enzyme activities and viral titers in cell culture samples. Good correlations
with correlation coefficients R2>0.88 were obtained between the amounts of biomarker
enzymes detected in the supernatants or in both the supernatants and cell lysates (as total per
well) and the corresponding plaque forming units (Fig 3). The best correlation (R2>0.98)
occurred with total GusA activity. Therefore, determination of the enzyme biomarker amount
of a cell culture sample can be used to estimate the viral titer of the sample. The intersection of
the linear regression curve of biomarker enzyme amount and titer and the linear range limit of
the biomarker enzyme assay was used to indicate the lower detection limit of titer that can be
Fig 3. Correlation between GLuc, GusA, and titer in GLV-1h351 and GLV-1h352 infected cells. A549 (triangles), CV-1 (circles) and PC-3 cells (squares)
were infected with GLV-1h351 or GLV-1h352 using an MOI of 0.005. The supernatants and cell lysates were assayed for GLuc, GusA and plaque forming
units at 8, 24, 48, 72, and 96 hours post infection. The “total” amount per well is the sum of the supernatant and cell lysate values. The grey line(s) in each
graph indicates the linear range limit of each assay. Correlation coefficients (R2) were calculated using the data points above the linear range limits (indicated
by crosses).
doi:10.1371/journal.pone.0137573.g003
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estimated by assaying the enzyme biomarker amount. For GLuc total amount and GusA super-
natant amount, approximately 103 pfu can be detected. For GusA total amount, approximately
102 pfu can be detected.
The relationship between enzyme biomarker activity and viral titer is affected by the nature
of the enzyme. Since GusA is a cytoplasmic protein, its release into the supernatants is depen-
dent on cell lysis. Therefore, measurement of GusA activity in the extracellular medium, espe-
cially during early infection (8–14 hpi when cells are not yet lysed), does not represent the viral
replication correctly. Hence, the correlation between GusA activity in the supernatant and viral
titer was only moderate (R2 = 0.88). However, the correlation considerably improved when
assaying total GusA activity (cells plus supernatant, R2 = 0.98). For GLuc, a secreted enzyme,
the enzyme activity in the supernatant is not dependent on cell lysis, therefore the correlation
with viral titer should not be affected whether the activity is assessed from the supernatant only
or from cells and supernatants combined. Indeed, the correlations between viral titer and GLuc
supernatant and GLuc total were comparable (R2 = 0.88 and R2 = 0.89, respectively). Further-
more, because the total activities of the biomarker enzymes each correlated with viral replica-
tion, then in turn, they should correlate with each other. Indeed, the correlation coefficient
between GLuc and GusA total amount (R2 = 0.80) was comparable, and no greater than, the
lowest correlation of GLuc and viral titer.
GusA and GusPlus as monitoring tools for VACV induced tumor cell death. Since glu-
curonidases are non-secreted enzymes and will only be released when the infected cells lyse,
the glucuronidase signal in the cell culture medium may be a good indicator of virus induced
cell lysis. This was investigated by correlating the amounts of GusA or GusPlus activity with
lactate dehydrogenase (LDH), an endogenous intracellular enzyme typically used as a marker
for cell lysis. Culture supernatants of GLV-1h68 or GLV-1h408 infected cells in culture were
assayed for GusA or GusPlus, respectively, and LDH during the course of infection (Fig 4A).
There was a good correlation between the GusA and GusPlus amounts and LDH in the super-
natants of infected A549, PC-3 and CV-1 cells at all stages of virus infection. The correlation
coefficients between GusPlus and LDH ranged from 0.94 for PC-3 cells to 0.96 for A549 and
CV-1 cells. For GusA and LDH the correlation coefficients were 0.81 for PC-3, 0.99 for CV-1,
and 0.99 for A549 cells. Therefore, the release from cells of the virally expressed biomarker
enzymes, GusPlus and GusA, paralleled the release of the cellular enzyme, LDH, as expected
since the release was caused by the virus-induced cell lysis.
The results of these experiments again confirmed that GusPlus provided a stronger fluores-
cent signal per pfu than GusA (Fig 4B). Nonetheless, the amount of biomarker enzyme as
determined in the assays of GusPlus and GusA using the purified enzymes as standards yielded
comparable enzyme amounts at each time point after simultaneous infection (Fig 4B). This is
expected since both enzymes are encoded by genes that are under control of the same P11 pro-
moter, hence the same amount of enzyme synthesis per replicating virus would result.
Comparison of biomarker enzymes in tumor-bearing animals
Amain objective of this work was to evaluate the use of the drug-encoded marker proteins for
monitoring of oncolytic virotherapy in patients. We therefore injected tumor-bearing nude
mice with GLV-1h68, GLV-1h351 or GLV-1h408 and assayed for the presence of the bio-
marker enzyme in serum over a period of 4 weeks. Unexpectedly in mice injected with GLV-
1h351, the concentration of GusA in serum was significantly higher, on average 7-fold (7 dpi)
to 40-fold (28 dpi), than the GLuc-concentration (Fig 5A). Interestingly, in mice injected with
GLV-1h351, levels of GLuc in serum increased more rapidly than the GusA levels (Fig 5A),
which was most evident at 14 dpi. This occurred consistently in 8 of the 9 mice examined (S2
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Fig). In contrast to the secreted GLuc protein, GusA is a cytoplasmic protein released into the
serum only upon tumor cell lysis, and a delay in the levels of GusA in serum relative to GLuc
can be explained by this fact. At 21 dpi, the levels of both enzymes reached their maxima and
similarly declined at 28 dpi.
Fig 4. Glucuronidase activity as an indicator of cell death and rVACV titer. A) The activities of lactate
dehydrogenase and GusA (orange) or GusPlus (blue) in the supernatant of infected A549 (top panel), PC-3
(middle) and CV-1 (lower panel) cells correlated well (R2>0.8), which indicates that glucuronidase can be
used as an indicator of (virus mediated) cell lysis. B) Due to its higher specific activity, GusPlus resulted in
higher fluorescent product signal when compared to GusA specific signals in the same cells at the same time
post infection. At the same time, the plaque forming units or glucuronidase ratios were similar (ratio about 1)
in GLV-1h68 or GLV-1h408 infected cells. Data represent the average plus standard deviation of GLV-1h408/
GLV-1h68-ratios obtained from simultaneously infected cells at different times post infection (n = 15).
Asterisks indicate statistical differences (p<0.005) between fluorescence ratios and pfu- or glucuronidase
ratios.
doi:10.1371/journal.pone.0137573.g004
Fig 5. Biomarker enzyme detection in tumor-bearing animals. A549 tumor-bearing animals were injected
with GLV-1h68, GLV-1h351 or GLV-1h408. Every week, serum was isolated and tested for biomarker
enzyme activity. A)GLV-1h351 injected mice were analyzed for the presence of GLuc and GusA activity. B)
Significantly less GusPlus activity in serum of GLV-1h408 injected mice was observed at all time points
compared to GusA in GLV-1h68 and GLV-1h351 injected mice (upper chart). At the same time points, no
differences were observed in Renilla luciferase activity in GLV-1h68 and GLV-1h408 injected mice (lower
chart). Grey crosses indicate that GLV-1h351 injected mice were not imaged for Renilla luciferase activity.C)
Analysis of biomarker enzymes and viral titers in tumors at the end of the experiment. The activities of GLuc
and GusPlus are clearly underrepresented relative to viral titers compared to GusA.D) Individual mouse data
from samples that were obtained at the end of the experiment (28 dpi).
doi:10.1371/journal.pone.0137573.g005
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A comparison of the amount and timing of increase of glucuronidase serum levels in A549
tumor-bearing mice was examined for each of the three viruses. Glucuronidase levels in serum
showed comparable increases at 7, 14 and 21 dpi and no statistically significant differences
between animals injected with GLV-1h68 or GLV-1h351 (both expressing GusA) (Fig 5B,
upper panel). Surprisingly, however, the glucuronidase serum levels of mice injected with
GLV-1h408 (expressing GusPlus) were significantly less and increased only through 14 dpi,
declining thereafter to 28 dpi. This was unexpected since in cell culture GusPlus levels were
greater than GusA in the cell lines tested, including A549 cells. We examined whether in vivo
GLV-1h408 might be less effective in colonizing tumors than GLV-1h68. Low light imaging of
the GLV-1h68 and GLV-1h408 injected mice was conducted to measure the amount of light
emission due to the production of Renilla luciferase, which was expressed by both viruses. No
substantial differences between GLV-1h68 or GLV-1h408 colonized tumors were observed by
Renilla luciferase imaging over the whole experiment (Fig 5B, lower panel). This indicated that
the concentration of virus within the tumors was comparable in both groups.
Biomarker enzyme and vaccinia virus titer were also analyzed in the tumors at the end of
the experiment (Fig 5C). Consistent with the results from the serum and the Renilla luciferase
imaging, the glucuronidase activity in GLV-1h68 colonized tumors (GusA) was much higher
than the activity in tumors colonized with GLV-1h408 (GusPlus), while the virus titers were
comparable. Moreover, we analyzed data of samples from individual mice obtained 28 dpi (Fig
5D). The results show correlation between the number of plaques/tumor and GusA (R2 = 0.55)
and GLuc (R2 = 0.67), respectively. The correlation between GusPlus in the serum and the
number of plaques in tumors for GLV-1h408 was less pronounced (R2 = 0.25).
In both analyses of serum and colonized tumors, the activity of GusA was considerably
greater than GLuc and GusPlus, although all enzymes were expressed under the same pro-
moter. An explanation could be a difference in the stability of the biomarker enzymes in vivo.
Determination of reporter enzymes half-life in mice. Consequently, we analyzed the
serum half lives of GusA, GLuc and GusPlus in BALB/c mice. Purified enzymes were injected
intravenously, serum was collected at various time points post-injection, assayed for glucuroni-
dase or GLuc activity, and the circulation half-life times were determined. Compared to GusA
(half-life: 69.6 ± 8.6 min) GLuc and GusPlus had about one sixteenth (4.3 ± 0.4 min) and one
third (21.7 ± 6.5 min) half-life times respectively (Table 3).
Notably, the observed 4.3 min half-life time for GLuc was shorter than the 20 min, which
were reported previously [19]. The reason for this difference may be that we used purified
GLuc protein instead of cell culture supernatant, as was used in the published study, and our
analysis was done in BALB/c mice instead of nude mice. Nevertheless, the considerably greater
half-life time of GusA in serum compared to GLuc and GusPlus allowed a greater accumula-
tion of GusA at equivalent states of virus replication. This translated into a more sensitive mon-
itor of virus replication (and tumor cell lysis) than assays of GLuc and GusPlus.
Table 3. Properties of the different marker proteins and their assays.
GLuc GusA GusPlus
LOD* 30–100 pg 2 pg 0.08 pg
linear range > 3 logs** 3.5 logs 3.5 logs
localization secreted cytoplasmic cytoplasmic
In vivo Half-life time (min) 4.3 ± 0.4 (n = 5) 69.6 ± 8.6 (n = 10) 21.7 ± 6.5 (n = 12)
* Limit of detection for the described standard assays. For the glucuronidases, the detection limit was lower when incubation time was increased.
** The maximum concentration tested here was 1 μg/assay. According to Tannous, the linear range was at least 5 orders of magnitude [18].
doi:10.1371/journal.pone.0137573.t003
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Glucuronidase assay (GusA) in human blood and plasma. Finally, we evaluated the per-
formance of the glucuronidase assay when GusA is spiked into fresh human blood and blood
plasma, respectively. Non-specific binding of glucuronidase to blood cells or inactivation of
GusA-activity in plasma, for example, would make the assay useless for identification of GusA
in human patients. Therefore, we obtained EDTA-blood from 4 healthy donors (San Diego
Blood Bank, San Diego, CA, USA). The blood was divided in 2 aliquots, one of which was used
to obtain blood plasma. Both EDTA-blood and plasma were spiked with varying concentra-
tions of GusA. The EDTA-blood samples were then centrifuged and the supernatant was used
in the glucuronidase assay, which was performed as described using Cl-MUGlcU as substrate
with the difference that the assay was performed in a 96-well plate format (instead of 384-well
plates) in a total volume of 150 μl that included 10 μl sample volume. Each sample and GusA-
concentration was analyzed in triplicate. In parallel, we analyzed GusA-spiked PBS with 2%
FBS (Assay Matrix) samples.
The results in Fig 6A clearly show that neither blood nor serum negatively affected the fluo-
rescence signal that was obtained from the assay. However, the fluorescence signal from the
blood samples was significantly higher than the plasma and assay matrix samples (Fig 6B).
This can be explained by the fact that normal hematocrit levels in humans are about 36 to 50%.
As glucuronidase does not enter the blood cells, the concentration in the supernatant is about
1.6 to 2.0 fold higher when the enzyme is spike into a given volume of blood, compared to spik-
ing into assay matrix or plasma. In conclusion, we showed that the GusA assay is not adversely
affected by blood components including human blood cells or human blood plasma.
Discussion
For the intended application to use rVACV-encoded enzymes as a monitor of oncolytic tumor
therapy by measuring the serum activity, the GusA was better suited than GusPlus and GLuc.
The greater circulation half-life time in vivo of GusA allowed increased accumulation of the
enzyme concentration in serum. GusA also had the additional benefit over GLuc of its
Fig 6. Glucuronidase assay in human blood and plasma. (A) GusA was spiked at varying concentrations
into assay matrix (PBS with 2% FBS), human plasma and human blood respectively. A glucuronidase assay
of the samples was performed using Cl-MUGlcU as substrate. The supernatant of spiked blood was used in
the glucuroronidase assay after centrifugation (7 min, 3000 g). Mean plus standard deviation of 4 samples is
shown with each concentration of glucuronidase tested in triplicate (n = 12 for each data point). (B) The data
for 104 pg/ml glucuronidase are shown in detail. The fluorescence signal derived from the blood sample is
significantly higher compared to the signal that was obtained after spiking the same amount of GusA into
identical volumes of assay matrix and plasma respectively. No significant difference was observed between
the samples of the latter two groups.
doi:10.1371/journal.pone.0137573.g006
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dependency on cell lysis for release into the circulation. Thus, GusA activity in serum was an
indicator not only of rVACV infection and replication, but also tumor cell lysis. In patients the
activity of the biomarker in the blood would be a more direct indicator of virus-mediated onco-
lysis than LDH-measurements. As a monitor of oncolytic therapy, information pertinent to all
the characteristics mentioned above would be extremely valuable. In this regard, it was also
very important to show that human blood does not have a negative impact on the performance
of the GusA-assay.
We did not quantify the protein amounts of GLuc and GusA in GLV-1h351 and GLV-
1h352 infected cells, therefore we cannot exclude that the expression levels of GusA and GLuc
may be different. Even though the GLuc and gusA genes were under control of the same pro-
moter (P11), the reporter genes are located at different loci in the genome of GLV-1h351 and
GLV-1h352. Previously it was reported that the position of a Firefly luciferase gene insertion
resulted in expression level differences in Western Reserve strain based constructs that
expressed the HSV thymidine kinase but were deficient for the vaccinia virus thymidine kinase
[20]. We however, have not observed differences in gene expression between virus strains that
encoded fluorescent proteins under control of identical (non-P11) promoters at different gene
loci within the viral genome of Lister-based vaccinia virus strains (data not shown).
Despite its lesser sensitivity, GLuc might still be a useful biomarker for virotherapy of
tumors. Since GLuc is actively secreted from infected cells in the absence of tumor cell lysis, a
comparison of GLuc levels with GusA levels might in combination provide information that
would not be possible with each marker alone. For example, therapeutic efficacy of viral treat-
ments in which tumor cell infection and virus replication did not lead directly to oncolysis, but
rather to anti-tumor immunostimulation, a monitor of tumor cell infection in the absence of
cell lysis would be beneficial. This will be investigated in future studies.
Other markers such as carcinoembryonic antigen (CEA) have also been used to monitor
oncolytic viruses [21]. In our experience, CEA is not an ideal biomarker for biological therapies
for the following reasons. CEA is a human protein that is detectable at low levels even in
healthy individuals. In certain cancer patients (e.g. colorectal cancer), CEA levels are upregu-
lated and it has also been described that heavy smokers have upregulated CEA levels. This
makes it very problematic to correlate elevated CEA levels in biological therapies with actual
therapeutic effects. In addition, the CEA cDNA has a domain, which is repeated 3 times with
very similar / partly identical sequence stretches. When we produced a CEA-encoding recom-
binant vaccinia virus, we frequently observed recombination between those sequence stretches,
which resulted in a heterogenous population of viruses with varying numbers (1–3) of the
sequence domain (Nube et al., data not shown).
For in vitro use and in cell cultures, GusPlus with its greater specific enzyme activity, lesser
limit of detection in conjunction with the more fluorogenic substrates of the coumarin family
(Cl-MUGlcU, MUGlcU and CUGlcU), and high range of linearity was the superior marker.
The excellent correlation of glucuronidase activity with viral titer (which we show here for the
first time) supports the replacement of the labor-intensive and time-consuming plaque assay
that is commonly used to monitor viral replication by a fluorogenic enzymatic assay. The fact
that we tested 5 glucuronidase substrates from 3 different compound classes and that the limit
of detection for those compounds varied over 2 orders of magnitude while the linear range for
all of the substrates was>3 orders of magnitude, makes the described assays a very versatile
tool for quantification of replication competent biological agents, including oncolytic viruses.
The extreme sensitivity of the GusPlus assay, which we analyzed here, might also be used for
the development of e.g. an ultra-sensitive ELISA employing GusPlus as a reporter instead of
horseradish peroxidase (HRP) as a conjugate to secondary antibodies for applications in pro-
tein detection methods (Western blot, ELISA), especially for proteins of low abundance.
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Considering the HRP detection limit of 1.7 pg/ml (http://www.piercenet.com/guide/guide-
elisa-substrates) and a molecular weight of 44kDa, GusPlus with an LOD of 0.5 pg/ml (40 fg/
80μl assay) and a molecular weight of 69.5kDa for the His-tagged GusPlus, the glucuronidase
can be detected about 5-times more sensitively on a per molecule basis.
All three enzymes are promising candidates to fulfill rapidly growing demand for sensitive
and reliable monitoring tools in the translational research and the clinical testing not only in
the field of the oncolytic virotherapy but also of other biological therapies such as gene and
stem cell therapy. The choice of the monitoring method is strongly dependent on the type and
the strategy of the biological therapy. Secreted biomarkers (such as GLuc) are useful for moni-
toring of cell survival as only actively secreting cells could be detected. The release of cyto-
plasmic enzymes such as glucuronidases indicates cell lysis, which can either indicate failure of
therapy (e.g. stem cell therapy) or successful therapy as in our case.
Supporting Information
S1 Fig. The orientation of the GLuc expression cassette inserted into the TK-locus of
rVACV had no effect on the expression levels of the reporter enzyme or on the viral replica-
tion efficacy. Cells (A549, CV-1 and PC-3) infected with either GLV-1h351 (blue squares) or
GLV-1h352 (orange circles) produced comparable relationships of GLuc activity, GusA activity
or virus titer between cells infected with GLV-1h351 or GLV-1h352. No significant differences
were observed (p>0.47).
(TIF)
S2 Fig. GLuc and GusA activities in serum of individual mice over time. In 8 out of 9 mice,
the GLuc concentration as determined by its activity increased faster than the GusA concentra-
tion (see data at 14 days post injection).
(TIF)
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